Innovations in Chronic Pain Therapeutics
White Mountain Pharma’s patent for pharmaceutical compositions treating chronic or unresolvable pain was issued on May 9, 2017.
Phase I/II clinical trial results using White Mountain Pharma’s testosterone gel therapeutic are now in press: “Treatment of pain in fibromyalgia patients with testosterone gel: Pharmacokinetics and clinical response”,
H.D. White, et al., International Immunopharmacology, 2015.
“A novel use for testosterone to treat central sensitization of chronic pain in fibromyalgia patients”, H.D. White, T.D. Robinson, International Immunopharmacology, 2015.
The full text of these publications has been viewed by over 13,000 scientists.
White Mountain Pharma has developed a therapeutic testosterone gel that targets novel mechanisms for treating chronic pain while avoiding the side effects of existing therapeutics.
White Mountain Pharma’s proprietary therapy and initial clinical study target these novel underlying disease mechanisms using the preferred FDA model for chronic widespread pain, Fibromyalgia (FM).
"Fibromyalgia is a common, chronic pain disorder that is characterized by widespread pain and tenderness. The availability of three FDA-approved medications for the management of fibromyalgia has improved outcomes for many patients with fibromyalgia. However, there continues to be a substantial unmet need in many fibromyalgia patients who do not tolerate or respond to these medications. WMP’s testosterone gel is a new and unique approach to the treatment of fibromyalgia. The initial clinical data from studies of the testosterone gel in patients with fibromyalgia provide evidence that WMP's new product treats the symptoms of fibromyalgia without the known side effects of current medications.”
Lesley M. Arnold, M.D., Professor of Psychiatry and Behavioral Neuroscience, Director of the Women's Health Research Program at the University of Cincinnati College of Medicine in Cincinnati, OH, Clinical Specialty in Fibromyalgia